Accueil   Diary - News   All news NH THERAGUIX announces the enrolment in Boston of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis

NH THERAGUIX announces the enrolment in Boston of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis

 

 

and
NANOSMART Phase Ib/II targeting pancreatic cancer and cancerous lung lesions

 

NH TherAguix (“NHT”), a French clinical stage company specialising in the development of innovative nanomedicines for the radiotherapy treatment of cancer indications, announces today the enrolment of the 2 first patients in the NANOBRAINMETS Phase II trial targeting brain metastases and the NANOSMART Phase I/II trial targeting pancreatic cancer and cancerous lung lesions, sponsored by Dana-Farber Brigham Cancer Center and led by radiation oncologists Drs. Ayal Aizer and Jonathan E. Leeman, respectively.

 

These 2 randomized clinical trials will investigate the efficacy of the combination of AGuIX® intravenous injection with standard of care radiotherapy to increase survival and quality of life of patients.

 

Read the press release